FluoGuide Submits IND Application for FG001 Cancer Imaging Agent to Begin U.S. Registration Trial
核心洞察
FluoGuide (搜索) has submitted an Investigational New Drug (IND) application to the FDA for FG001, marking the transition to late-clinical development for their cancer imaging technology.
The company received FDA alignment on their Phase 2 clinical trial design in high-grade glioma and key elements of the subsequent Phase 3 program during pre-IND meetings.
FG001 is designed to improve surgical precision by lighting up cancer intraoperatively, potentially reducing local recurrence and surgical complications.
FluoGuide (搜索) A/S announced on January 21, 2026, that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FG001, its lead cancer imaging agent. The IND submission supports the initiation of the company's first registration trial in patients with high-grade glioma (HGG), representing a key regulatory milestone that marks FG001's transition to late-clinical development.
The Danish biotech company expects to enroll the first patient in Q2 2026, maintaining its timeline for advancing toward U.S. registration. FG001 is designed to improve surgical precision by lighting up cancer intraoperatively, offering a dual benefit of reducing both the frequency of local recurrence post-surgery and lessening surgical sequelae.
FDA Alignment Provides Regulatory Foundation
Prior to the IND submission, FluoGuide (搜索) held a pre-IND meeting with the FDA, during which the agency reviewed a comprehensive development package covering completed work and proposed plans for ongoing studies. Importantly, the company received FDA alignment on the design of its U.S. Phase 2 clinical trial in HGG to support registration, as well as on key elements of the subsequent Phase 3 program.
"This regulatory alignment provides a strong foundation for the long-term development planning, and in our view, de-risks the regulatory process as we advance toward NDA submission and future U.S. approval of FG001," the company stated.
Significant portions of the submitted IND package, including the preclinical section, are expected to form the basis of the future New Drug Application (NDA) required to obtain approval to market FG001 in the U.S.
Clear Path to U.S. Approval
FluoGuide (搜索) anticipates that two clinical trials will be required to support U.S. approval of FG001 for HGG. Both trials are expected to enroll patients over approximately one year, with final timelines and enrollment subject to emerging data and regulatory feedback. This program establishes what the company describes as a clear, structured and capital-efficient path toward U.S. approval of FG001 in HGG, which it characterizes as one of the most aggressive forms of cancer.
"The IND submission reflects focused execution across regulatory, clinical and technical disciplines. I am very proud of the FluoGuide (搜索) team and our collaborating neurosurgeons for delivering a high-quality IND package that reflects the maturity of the FG001 program and supports a clear path toward U.S. registration trials in high-grade glioma – advancing our mission to maximize the outcomes for patients facing this highly aggressive brain cancer," said Donna Haire, COO of FluoGuide.
Technology Platform and Clinical Evidence
FG001 is built on FluoGuide (搜索)'s uPAR (搜索) technology platform and has demonstrated effectiveness and tolerability in several Phase II clinical trials. The lead indications for FG001 include aggressive brain cancer (glioblastoma) and oral head and neck cancer. The improved surgical precision offered by the technology ultimately enhances the likelihood of complete cure and may lower healthcare costs, according to the company.
"As we enter 2026, FluoGuide (搜索) has reached a key inflection point. With the IND now submitted, we have further de-risked our lead program and established a well-defined regulatory path toward U.S. approval. Our mission remains unchanged: to maximizing outcomes in cancer surgery," said Morten Albrechtsen, CEO of FluoGuide. "We are now well positioned to advance toward registration."
The company has entered partnerships with leading MedTech companies to accelerate development and commercialization. FluoGuide (搜索) is listed on Nasdaq First North Sweden under the ticker "FLUO" and will continue preparations for the planned U.S. Phase 2 registration trial in high-grade glioma, providing updates as appropriate.